Plasma Melatonin AND Mortality After Acute Myocardial Infarction
Early-morning Plasma Melatonin Levels Predict Cardiovascular Mortality After Acute Myocardial Infarction
1 other identifier
observational
732
0 countries
N/A
Brief Summary
Pre-clinical and clinical studies have demonstrated that melatonin has cardio-protection effects. Melatonin has anti-inflammatory, antioxidant, antihypertensive, antithrombotic and antilipaemic properties, which plays important roles in a variety of cardiovascular pathophysiologic processes. Nocturnal melatonin levels decreased after AMI, and lower serum melatonin concentrations after AMI are associated with more heart failure and cardiac death and left ventricular remodeling. Moreover in women with increased BMI, lower melatonin secretion is associated with higher risks of MI. Early-morning blood collection is easier in clinical practice. Therefore, the investigators carried out a cohort study to evaluate the prognostic value of plasma soluble melatonin in hospitalized patients with acute myocardial infarction (AMI).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2013
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
July 24, 2017
CompletedFirst Posted
Study publicly available on registry
July 26, 2017
CompletedJuly 28, 2017
July 1, 2017
2 years
July 24, 2017
July 25, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
cardiovascular mortality
The median follow-up was 31.6 months
Secondary Outcomes (4)
non-cardiovascular mortality
The median follow-up was 31.6 months
Myocardial infarction
The median follow-up was 31.6 months
heart failure readmission
The median follow-up was 31.6 months
Stroke
The median follow-up was 31.6 months
Interventions
Eligibility Criteria
A single center study on PCI-treated myocardial infarction patients
You may qualify if:
- consecutive patients of acute AMI come to department of cardiology, 301 hospital (Beijing, China),absent of cardiogenic shock, and survival for at least 24 h after percutaneous coronary intervention treatment.
You may not qualify if:
- patients with autoimmune diseases, collagen tissue diseases, drug addiction, radiotherapy, patients receiving immunosuppressive treatment, taking sedatives, antiepileptic drugs, tricyclic antidepressants or any medication known to influence melatonin metabolism, psychiatric sleeping disorders, shift workers, and subjects with jet-lag syndrome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
July 24, 2017
First Posted
July 26, 2017
Study Start
January 1, 2013
Primary Completion
January 1, 2015
Study Completion
January 1, 2017
Last Updated
July 28, 2017
Record last verified: 2017-07